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A 47-year-old south-east Asian gentleman treated for COVID-19
(Figure 1) was re-admitted 2 days after discharge with an ST-elevation
myocardial infarction (STEMI) (Figure 2). Emergency percutaneous
coronary intervention revealed thrombus in the left main stem (LMS)
extending down the left anterior descending, circumflex, and inter-
mediate coronary arteries, compromising flow; the right coronary
artery was unobstructed (Video 1). Aspiration thrombectomy was
performed: using a 6-Fr Extra Back-Up 3.5 guide catheter
(Medtronic, USA) and a ChoICE PT extra floppy guidewire (Boston
Scientific, USA), an Export aspiration catheter (Medtronic, USA) was
railroaded to aspirate thrombus from the LMS, restoring coronary
flow. In addition to the dual anti-platelet (DAPT) regime, a 12-hour
tirofiban infusion was completed followed by a heparin infusion for
24-hours and then addition of a direct oral anticoagulant (DOAC) to
the DAPT. A subsequent multi-disciplinary team discussion with car-
diac surgeons advised a repeat assessment of the coronary vessels.
This was performed 2 weeks later with intravascular ultrasound
(Video 2) and revealed a significant reduction in thrombus burden
with normal flow in all affected coronary arteries. The echocardio-
gram on admission demonstrated left ventricle (LV) function impair-
ment and akinesia of the ventricular apex (Video 3). He was
discharged on triple therapy (DAPT and DOAC) with planned
Aspirin discontinuation after 2 weeks. He remains well to date with
some LV function improvement at 3-month follow-up.
Thromboembolism is a significant manifestation of the COVID-
19 disease and associated with an increased risk of mortality.1
Arterial thrombosis causing major vascular events have been
reported with increasing prevalence.2 LMS thrombus-mediated
STEMI is life-threatening but rare in COVID-19. There is delayed
risk of thrombosis in SARS-Cov-2 infection3 and our case high-
lights this risk exists in the arterial system which extends beyond
the period of hospitalization.
Conclusion
COVID-19 illness is a prothrombotic state increasing the risk of a
life-threatening myocardial infarction.
Consent: The authors confirm that written consent for submission
and publication of this case report including images and associated
text has been obtained from the patient in line with COPE guidance.
Figure 1: Chest radiograph demonstrating bilateral consolidation
consistent with COVID-19.
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Figure 2: Electrocardiogram on admission demonstrating ST-elevation consistent with the ST-elevation myocardial infarction.
Video 1: Primary percutaneous coronary intervention treating
left main stem thrombus with thrombectomy. ST-elevation myocar-
dial infarction with acute left main stem thrombus (red arrow)
treated with coronary thrombectomy; some residual thrombus
remains at the end of the procedure (red circle).
Video 2: Repeat coronary angiogram following thrombectomy
and pharmacotherapy. There is significant resolution of the throm-
bus burden with normal coronary flow. Intravascular ultrasound:
pull-back from the proximal left anterior descending; there is re-
sidual thrombus remaining (green arrow) in the left main stem
which is 6 mm in diameter. The minimum luminal cross-sectional
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Video 3: Echocardiography following percutaneous coronary
intervention. (A) Echocardiogram following primary percutaneous
coronary intervention demonstrating left ventricle impairment with
an estimated left ventricle ejection fraction of 30–35%; the apical
septum and true apex appear hypokinetic and akinetic. (B) At
3-month follow-up study, there is some recovery of left ventricle
function with an estimated left ventricle ejection fraction of
45–50%; the true apex is akinetic.
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